Results 141 to 150 of about 40,951 (233)

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, Volume 183, Issue 11, Page 2947-2968, June 2026.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

Commentary: The impact of dietary inflammation index on benign prostatic hyperplasia: insights from patient data and animal models. [PDF]

Front Nutr
Li Z, Wang L, Zhong L, Zheng D.
europepmc   +1 more source

Restless Legs Syndrome in Patients With PMP22‐Related Neuropathies

Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Background and Aims Restless legs syndrome (RLS) is frequently reported in peripheral neuropathies, but its prevalence and clinical correlates in Charcot–Marie–Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP) remain poorly defined.
Bogdan Bjelica, Milorad Vujnic, Milica Vukojevic, Ivo Bozovic, Nikola Andrejic, Ivana Basta, Vidosava Rakocevic‐Stojanovic, Stojan Peric   +7 more
wiley   +1 more source

The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. [PDF]

Am J Mens Health
Gao W, Guo Y, Yu X, Zhang T, Gong H, Zhang Y.   +5 more
europepmc   +1 more source

A Zosteriform Papular Cutaneous Eruption

JEADV Clinical Practice, Volume 5, Issue 2, Page 728-730, June 2026.
Silvia Borriello, Umberto Santaniello, Astrid Lappi, Paolo Borrelli, Angelo Battaglia, Roberta Patetta, Sophie Frassy, Simone Ribero, Pietro Quaglino   +8 more
wiley   +1 more source

Effect of the Mutual Interaction of GPNMB and LPAR1 on Cellular Motility and Tumorigenicity in Mammary Epithelial Cells

Pathology International, Volume 76, Issue 6, June 2026.
GPNMB and LPAR1 form a positive feedback loop enhancing LPA signaling. LPA–LPAR1 activates RhoA–ROCK, driving actin reorganization and cell motility. GPNMB–LPAR1 signaling promotes tumorigenic potential. ABSTRACT Glycoprotein non‐metastatic melanoma protein B (GPNMB) is a poor prognostic factor, which is highly expressed in many types of malignant ...
Minori Kimura, Yukari Okita, Erina Iwabuchi, Xinzhu Hong, Yumu Ichikawa, Manar A. Elhinnawi, Hironobu Sasano, Mitsuyasu Kato   +7 more
wiley   +1 more source

Establishment and validation of a risk scoring model for predicting the risk of bladder stones in patients with benign prostatic hyperplasia. [PDF]

Front Med (Lausanne)
Luo Y, Gao Y, Fang H, Shi C, Xu J, Li X, Li Y.   +6 more
europepmc   +1 more source

A Multi‐Institutional Retrospective Study of 21 Dogs Having Undergone Hypofractionated Radiotherapy for Adrenal Tumours (2017–2024)

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 229-239, June 2026.
ABSTRACT Radiation therapy (RT) has emerged as a promising non‐surgical approach for treating canine adrenal tumours. This multi‐institutional, retrospective study describes clinical outcomes for 21 dogs having been prescribed a course of hypofractionated image‐guided intensity‐modulated RT (IMRT) entailing delivery of 25–35 Gy total in 5 fractions ...
Yen‐Hao Erik Lai, Michael S. Kent, Michael W. Nolan, Dah‐Renn Fu, Jayme S. Looper   +4 more
wiley   +1 more source

Characterizing the academic literature on surgical management of benign prostatic hyperplasia: A bibliometric analysis. [PDF]

World J Urol
Tozsin A, Arslan E, Ermiş O, Akgül B, Güven S, Herrmann TR.   +5 more
europepmc   +1 more source

Update of the risk assessment on dioxins and dioxin‐like PCBs in feed and food

EFSA Journal, Volume 24, Issue 6, June 2026.
Abstract The European Commission asked EFSA to update its 2018 risk assessment on polychlorinated dibenzo‐p‐dioxins and dibenzofurans (PCDD/Fs) and dioxin‐like polychlorinated biphenyls (DL‐PCBs) in feed and food, based on the 2022 WHO Toxic Equivalency Factors (WHO2022‐TEFs).
EFSA Panel on Contaminants in the Food Chain (CONTAM Panel), Helle Katrine Knutsen, Agneta Åkesson, Vasileios Bampidis, Margherita Bignami, Laurent Bodin, James Kevin Chipman, Gisela Degen, Antonio Hernández‐Jerez, Tim Hofer, Christer Hogstrand, Stefano Landi, Jean‐Charles Leblanc, Kyriaki Machera, Evangelia Ntzani, Isabelle P. Oswald, Guido Rychen, Salomon Sand, Katharina Vejdovszky, Barbara Viviani, Jesús del Mazo, Andy Hart, Dieter Schrenk, José Cortiñas Abrahantes, Luisa Ramos Bordajandi, Francesca Riolo, Tuuli Tauriainen, Ron Hoogenboom   +27 more
wiley   +1 more source